Australia at a glance
- Population
- 27.6 million 2025
- Life expectancy at birth
- 83.1 years, 2024
- People aged 65 and over
- 18.1 % of people, 2025
- Health spending per person
- 6,980 US$ per person, 2023
- Doctors
- 4.09 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
Australia Antiviral Drugs Market Industry Trends and Forecast to 2034: Segmented by (Virus, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$359.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $727.9 Mn | — | — |
| 2025 (base) | $759.9 Mn | +$32.0 Mn | — |
| 2026 (forecast) | $793.3 Mn | +$33.4 Mn | +4.4% |
| 2027 (forecast) | $828.2 Mn | +$34.9 Mn | +9% |
| 2028 (forecast) | $864.7 Mn | +$36.4 Mn | +13.8% |
| 2029 (forecast) | $902.7 Mn | +$38.0 Mn | +18.8% |
| 2030 (forecast) | $942.5 Mn | +$39.7 Mn | +24% |
| 2031 (forecast) | $983.9 Mn | +$41.5 Mn | +29.5% |
| 2032 (forecast) | $1.03 Bn | +$43.3 Mn | +35.2% |
| 2033 (forecast) | $1.07 Bn | +$45.2 Mn | +41.1% |
| 2034 (forecast) | $1.12 Bn | +$47.2 Mn | +47.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $759.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.12 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Virus, route and end user (see all) |
| Key players | Gilead Sciences, Inc., GSK PLC, Merck & Co., Inc., Pfizer Inc., AbbVie Inc. and 1 more (see all) |
| Regulator in Australia | TGASource: Therapeutic Goods Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antiviral drugs treat infections caused by viruses such as HIV, hepatitis, influenza, herpes and COVID-19.
Key segments of the antiviral Drugs market include virus (HIV, Hepatitis B and C and Influenza) and route (Oral, Injectable and Topical).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antiviral Drugs market.
New vaccines, rapid tests and public-private funding for neglected diseases give the antiviral Drugs market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antiviral Drugs market.
The antiviral Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.[2]
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antiviral Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.
What doctors and scientists are doing in Antiviral Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
Australia · 2 shared keywords
Australia · 2 shared keywords
Australia · 2 shared keywords
Australia · 2 shared keywords
Australia · 2 shared keywords
Australia · 2 shared keywords
Medical Devices · Australia
Medical Devices · Australia
OTC & Nutraceuticals · Australia
Medical Devices · Australia
Healthcare Services · Australia
Medical Devices · Australia